ComFluCOV试验中COVID-19与流感疫苗同时接种后唾液SARS-CoV-2特异性黏膜抗体的检测
ComFluCOV试验将679名受试者随机分配,在接种第二剂COVID-19疫苗时同时接种适龄流感疫苗或安慰剂。本研究报告次要结局:同时接种流感疫苗不影响接种3周后唾液抗刺突IgG阳性率(辉瑞/BioNTech BNT162b2为99.1% cf. 95.6%,阿斯利康ChAdOx1为67.8% cf. 64.9%),唾液IgG与血清滴度正相关;两种COVID-19疫苗均未诱导黏膜IgA。
要点
- 同时接种流感疫苗不影响唾液抗刺突IgG阳性率。
- 唾液IgG与血清滴度正相关,提示唾液可用于评估免疫原性差异。
- 两种COVID-19疫苗均未检测到黏膜IgA应答。
核心结论
- 同时接种流感疫苗不影响COVID-19疫苗诱导的唾液抗刺突IgG阳性率。
- 唾液IgG与血清滴度正相关,提示唾液可用于未来疫苗研究中评估免疫原性差异。
- 两种COVID-19疫苗均未诱导黏膜IgA,作者认为这强化了对能诱导灭菌免疫或减少传播的新型疫苗的需求。
研究设计与样本
- ComFluCOV试验将679名受试者随机分配,在接种第二剂COVID-19疫苗时同时接种适龄流感疫苗或安慰剂。
- 本研究报告该试验的次要结局,采用内部ELISA检测唾液中的抗刺突IgG和IgA水平。
- 试验注册号为ISRCTN 14391248。
主要发现
- 接种3周后,同时接种流感疫苗组与安慰剂组相比,唾液抗刺突IgG阳性率对辉瑞/BioNTech BNT162b2为99.1% cf. 95.6%,对阿斯利康ChAdOx1为67.8% cf. 64.9%。
- 唾液IgG与血清滴度呈正相关。
- 两种COVID-19疫苗均未检测到黏膜IgA应答。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ComFluCOV trial randomized 679 participants to receive an age-appropriate influenza vaccine, or placebo, alongside their second COVID-19 vaccine. Concomitant administration was shown to be safe, and to preserve systemic immune responses to both vaccines. Here we report on a secondary outcome of the trial investigating SARS-CoV-2-specific mucosal antibody responses. Anti-spike IgG and IgA levels in saliva were measured with in-house ELISAs. Concomitant administration of an influenza vaccine did not affect salivary anti-spike IgG positivity rates to Pfizer/BioNTech BNT162b2 (99.1 cf. 95.6%), or AstraZeneca ChAdOx1 (67.8% cf. 64.9%), at 3-weeks post-vaccination relative to placebo. Furthermore, saliva IgG positively correlated with serum titres highlighting the potential utility of saliva for assessing differences in immunogenicity in future vaccine studies. Mucosal IgA was not detected in response to either COVID-19 vaccine, reinforcing the need for novel vaccines capable of inducing sterilising immunity or otherwise reducing transmission. The trial is registered as ISRCTN 14391248.
引用
- Baum HE, Thirard R, Halliday A, et al. Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial. Vaccine. 2024. PMID: 38580516. doi:10.1016/j.vaccine.2024.03.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。